Tavneos

News

EMA looks into 'data integrity' issue with Amgen's Tavneos

Concerns about efficacy data in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered a review in the EU.

News

CSL Vifor plans UK launch after NICE backs rare disease drug...

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavne

News

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.

News

Flash FDA approval sends ChemoCentryx spiralling upwards

ChemoCentryx has claimed FDA approval for its avacopan drug for a rare autoimmune disease, becoming the first orally-active drug that targets the complement C5 receptor.

EMA looks into 'data integrity' issue with Amgen's Tavneos

CSL Vifor plans UK launch after NICE backs rare disease drug...

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Flash FDA approval sends ChemoCentryx spiralling upwards

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Tavneos

Editor's Picks